Why Is Chewy Stock Up — And Will It Keep Climbing?
We are all witnesses to the crazy e-commerce industry boom…
Buy
62
CORBF Quote, Financials, Valuation and Earnings
Last price:
$1.05
Seasonality move
:
-3.66%
Day range:
$1.05 - $1.05
52-week range:
$0.25 - $2.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.66x
P/B ratio:
0.18x
Volume:
100
Avg. volume:
248.3K
1-year change:
-16%
Market cap:
$140.6M
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CORBF
Global Cord Blood
|
-- | -- | -- | -- | -- |
|
HCM
HUTCHMED (China)
|
-- | -- | -- | -- | $26.36 |
|
HKPD
Hong Kong Pharma Digital Technology Holdings
|
-- | -- | -- | -- | -- |
|
PRE
Prenetics Global
|
$12M | -- | 74.63% | -- | $13.00 |
|
RGC
Regencell Bioscience Holdings
|
-- | -- | -- | -- | -- |
|
SBMFF
Sino Biopharmaceutical
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CORBF
Global Cord Blood
|
$1.05 | -- | $140.6M | -- | $0.00 | 0% | 0.66x |
|
HCM
HUTCHMED (China)
|
$14.61 | $26.36 | $2.5B | 73.05x | $0.00 | 0% | 4.05x |
|
HKPD
Hong Kong Pharma Digital Technology Holdings
|
$0.99 | -- | $10.9M | 5.70x | $0.00 | 0% | 0.52x |
|
PRE
Prenetics Global
|
$5.00 | $13.00 | $61.1M | -- | $0.00 | 0% | 2.41x |
|
RGC
Regencell Bioscience Holdings
|
$29.01 | -- | $377.5M | -- | $0.00 | 0% | -- |
|
SBMFF
Sino Biopharmaceutical
|
$0.49 | -- | $9B | 18.56x | $0.00 | 2.08% | 2.25x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CORBF
Global Cord Blood
|
-- | -0.478 | -- | -- |
|
HCM
HUTCHMED (China)
|
9.83% | -0.260 | 3.34% | 2.67x |
|
HKPD
Hong Kong Pharma Digital Technology Holdings
|
-- | 0.000 | -- | -- |
|
PRE
Prenetics Global
|
-- | -0.748 | -- | 1.11x |
|
RGC
Regencell Bioscience Holdings
|
-- | -28.439 | -- | -- |
|
SBMFF
Sino Biopharmaceutical
|
23.1% | -0.165 | 14.66% | 1.14x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CORBF
Global Cord Blood
|
-- | -- | -- | -- | -- | -- |
|
HCM
HUTCHMED (China)
|
-- | -- | 4.51% | 4.99% | -- | -- |
|
HKPD
Hong Kong Pharma Digital Technology Holdings
|
-- | -- | -- | -- | -- | -- |
|
PRE
Prenetics Global
|
$3.9M | -$11.8M | -23.16% | -23.16% | -154.7% | -- |
|
RGC
Regencell Bioscience Holdings
|
-- | -- | -- | -- | -- | -- |
|
SBMFF
Sino Biopharmaceutical
|
-- | -- | 6.83% | 8.57% | -- | -- |
Global Cord Blood vs. Competitors
-
Which has Higher Returns CORBF or HCM?
HUTCHMED (China) has a net margin of -- compared to Global Cord Blood's net margin of --. Global Cord Blood's return on equity of -- beat HUTCHMED (China)'s return on equity of 4.99%.
Company Gross Margin Earnings Per Share Invested Capital CORBFGlobal Cord Blood-- -- -- HCMHUTCHMED (China)-- -- $854.7M -
What do Analysts Say About CORBF or HCM?
Global Cord Blood has a consensus price target of --, signalling downside risk potential of --. On the other hand HUTCHMED (China) has an analysts' consensus of $26.36 which suggests that it could grow by 80.45%. Given that HUTCHMED (China) has higher upside potential than Global Cord Blood, analysts believe HUTCHMED (China) is more attractive than Global Cord Blood.
Company Buy Ratings Hold Ratings Sell Ratings CORBFGlobal Cord Blood0 0 0 HCMHUTCHMED (China)10 2 0 -
Is CORBF or HCM More Risky?
Global Cord Blood has a beta of -0.640, which suggesting that the stock is 163.968% less volatile than S&P 500. In comparison HUTCHMED (China) has a beta of 0.658, suggesting its less volatile than the S&P 500 by 34.171%.
-
Which is a Better Dividend Stock CORBF or HCM?
Global Cord Blood has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. HUTCHMED (China) offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Global Cord Blood pays -- of its earnings as a dividend. HUTCHMED (China) pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CORBF or HCM?
Global Cord Blood quarterly revenues are --, which are smaller than HUTCHMED (China) quarterly revenues of --. Global Cord Blood's net income of -- is lower than HUTCHMED (China)'s net income of --. Notably, Global Cord Blood's price-to-earnings ratio is -- while HUTCHMED (China)'s PE ratio is 73.05x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Global Cord Blood is 0.66x versus 4.05x for HUTCHMED (China). Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CORBFGlobal Cord Blood0.66x -- -- -- HCMHUTCHMED (China)4.05x 73.05x -- --
-
Which has Higher Returns CORBF or HKPD?
Hong Kong Pharma Digital Technology Holdings has a net margin of -- compared to Global Cord Blood's net margin of --. Global Cord Blood's return on equity of -- beat Hong Kong Pharma Digital Technology Holdings's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CORBFGlobal Cord Blood-- -- -- HKPDHong Kong Pharma Digital Technology Holdings-- -- -- -
What do Analysts Say About CORBF or HKPD?
Global Cord Blood has a consensus price target of --, signalling downside risk potential of --. On the other hand Hong Kong Pharma Digital Technology Holdings has an analysts' consensus of -- which suggests that it could fall by --. Given that Global Cord Blood has higher upside potential than Hong Kong Pharma Digital Technology Holdings, analysts believe Global Cord Blood is more attractive than Hong Kong Pharma Digital Technology Holdings.
Company Buy Ratings Hold Ratings Sell Ratings CORBFGlobal Cord Blood0 0 0 HKPDHong Kong Pharma Digital Technology Holdings0 0 0 -
Is CORBF or HKPD More Risky?
Global Cord Blood has a beta of -0.640, which suggesting that the stock is 163.968% less volatile than S&P 500. In comparison Hong Kong Pharma Digital Technology Holdings has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock CORBF or HKPD?
Global Cord Blood has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Hong Kong Pharma Digital Technology Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Global Cord Blood pays -- of its earnings as a dividend. Hong Kong Pharma Digital Technology Holdings pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CORBF or HKPD?
Global Cord Blood quarterly revenues are --, which are smaller than Hong Kong Pharma Digital Technology Holdings quarterly revenues of --. Global Cord Blood's net income of -- is lower than Hong Kong Pharma Digital Technology Holdings's net income of --. Notably, Global Cord Blood's price-to-earnings ratio is -- while Hong Kong Pharma Digital Technology Holdings's PE ratio is 5.70x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Global Cord Blood is 0.66x versus 0.52x for Hong Kong Pharma Digital Technology Holdings. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CORBFGlobal Cord Blood0.66x -- -- -- HKPDHong Kong Pharma Digital Technology Holdings0.52x 5.70x -- --
-
Which has Higher Returns CORBF or PRE?
Prenetics Global has a net margin of -- compared to Global Cord Blood's net margin of -137.21%. Global Cord Blood's return on equity of -- beat Prenetics Global's return on equity of -23.16%.
Company Gross Margin Earnings Per Share Invested Capital CORBFGlobal Cord Blood-- -- -- PREPrenetics Global50.75% -$0.84 $180.1M -
What do Analysts Say About CORBF or PRE?
Global Cord Blood has a consensus price target of --, signalling downside risk potential of --. On the other hand Prenetics Global has an analysts' consensus of $13.00 which suggests that it could grow by 160%. Given that Prenetics Global has higher upside potential than Global Cord Blood, analysts believe Prenetics Global is more attractive than Global Cord Blood.
Company Buy Ratings Hold Ratings Sell Ratings CORBFGlobal Cord Blood0 0 0 PREPrenetics Global1 0 0 -
Is CORBF or PRE More Risky?
Global Cord Blood has a beta of -0.640, which suggesting that the stock is 163.968% less volatile than S&P 500. In comparison Prenetics Global has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock CORBF or PRE?
Global Cord Blood has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Prenetics Global offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Global Cord Blood pays -- of its earnings as a dividend. Prenetics Global pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CORBF or PRE?
Global Cord Blood quarterly revenues are --, which are smaller than Prenetics Global quarterly revenues of $7.8M. Global Cord Blood's net income of -- is lower than Prenetics Global's net income of -$10.7M. Notably, Global Cord Blood's price-to-earnings ratio is -- while Prenetics Global's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Global Cord Blood is 0.66x versus 2.41x for Prenetics Global. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CORBFGlobal Cord Blood0.66x -- -- -- PREPrenetics Global2.41x -- $7.8M -$10.7M
-
Which has Higher Returns CORBF or RGC?
Regencell Bioscience Holdings has a net margin of -- compared to Global Cord Blood's net margin of --. Global Cord Blood's return on equity of -- beat Regencell Bioscience Holdings's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CORBFGlobal Cord Blood-- -- -- RGCRegencell Bioscience Holdings-- -- -- -
What do Analysts Say About CORBF or RGC?
Global Cord Blood has a consensus price target of --, signalling downside risk potential of --. On the other hand Regencell Bioscience Holdings has an analysts' consensus of -- which suggests that it could fall by --. Given that Global Cord Blood has higher upside potential than Regencell Bioscience Holdings, analysts believe Global Cord Blood is more attractive than Regencell Bioscience Holdings.
Company Buy Ratings Hold Ratings Sell Ratings CORBFGlobal Cord Blood0 0 0 RGCRegencell Bioscience Holdings0 0 0 -
Is CORBF or RGC More Risky?
Global Cord Blood has a beta of -0.640, which suggesting that the stock is 163.968% less volatile than S&P 500. In comparison Regencell Bioscience Holdings has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock CORBF or RGC?
Global Cord Blood has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regencell Bioscience Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Global Cord Blood pays -- of its earnings as a dividend. Regencell Bioscience Holdings pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CORBF or RGC?
Global Cord Blood quarterly revenues are --, which are smaller than Regencell Bioscience Holdings quarterly revenues of --. Global Cord Blood's net income of -- is lower than Regencell Bioscience Holdings's net income of --. Notably, Global Cord Blood's price-to-earnings ratio is -- while Regencell Bioscience Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Global Cord Blood is 0.66x versus -- for Regencell Bioscience Holdings. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CORBFGlobal Cord Blood0.66x -- -- -- RGCRegencell Bioscience Holdings-- -- -- --
-
Which has Higher Returns CORBF or SBMFF?
Sino Biopharmaceutical has a net margin of -- compared to Global Cord Blood's net margin of --. Global Cord Blood's return on equity of -- beat Sino Biopharmaceutical's return on equity of 8.57%.
Company Gross Margin Earnings Per Share Invested Capital CORBFGlobal Cord Blood-- -- -- SBMFFSino Biopharmaceutical-- -- $7.2B -
What do Analysts Say About CORBF or SBMFF?
Global Cord Blood has a consensus price target of --, signalling downside risk potential of --. On the other hand Sino Biopharmaceutical has an analysts' consensus of -- which suggests that it could fall by --. Given that Global Cord Blood has higher upside potential than Sino Biopharmaceutical, analysts believe Global Cord Blood is more attractive than Sino Biopharmaceutical.
Company Buy Ratings Hold Ratings Sell Ratings CORBFGlobal Cord Blood0 0 0 SBMFFSino Biopharmaceutical0 0 0 -
Is CORBF or SBMFF More Risky?
Global Cord Blood has a beta of -0.640, which suggesting that the stock is 163.968% less volatile than S&P 500. In comparison Sino Biopharmaceutical has a beta of 0.536, suggesting its less volatile than the S&P 500 by 46.434%.
-
Which is a Better Dividend Stock CORBF or SBMFF?
Global Cord Blood has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sino Biopharmaceutical offers a yield of 2.08% to investors and pays a quarterly dividend of $0.00 per share. Global Cord Blood pays -- of its earnings as a dividend. Sino Biopharmaceutical pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CORBF or SBMFF?
Global Cord Blood quarterly revenues are --, which are smaller than Sino Biopharmaceutical quarterly revenues of --. Global Cord Blood's net income of -- is lower than Sino Biopharmaceutical's net income of --. Notably, Global Cord Blood's price-to-earnings ratio is -- while Sino Biopharmaceutical's PE ratio is 18.56x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Global Cord Blood is 0.66x versus 2.25x for Sino Biopharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CORBFGlobal Cord Blood0.66x -- -- -- SBMFFSino Biopharmaceutical2.25x 18.56x -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Netflix a Must-own Stock?
The early months of 2025 have been very hard on…
Why Did Bill Ackman Buy Uber Stock?
In February, Pershing Square manager Bill Ackman revealed that his…
Stock Ideas
Buy
61
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 34x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
59
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 38x
Alerts
Sell
27
SAIA alert for Apr 26
Saia [SAIA] is down 30.77% over the past day.
Sell
48
APPF alert for Apr 26
AppFolio [APPF] is down 18.16% over the past day.
Sell
15
KNSL alert for Apr 26
Kinsale Capital Group [KNSL] is down 16.33% over the past day.
